Compounds > olomoucine

olomoucine and Breast Neoplasms

olomoucine has been researched along with Breast Neoplasms in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (66.67)18.2507
2000's1 (33.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gueorguieva, M; Kramer, MP; Lindner, H; Ranftler, C; Sarg, B; Wesierska-Gadek, J1
Hung, MC; Jing, T; Liu, B; McDonnell, TJ; Tan, M; Yao, J; Yu, D1
David-Pfeuty, T1

Other Studies

3 other study(ies) available for olomoucine and Breast Neoplasms

ArticleYear
A new, unexpected action of olomoucine, a CDK inhibitor, on normal human cells: up-regulation of CLIMP-63, a cytoskeleton-linking membrane protein.
    Journal of cellular biochemistry, 2007, Dec-15, Volume: 102, Issue:6

    Topics: Animals; Breast Neoplasms; Cell Line, Transformed; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinases; DNA; Dose-Response Relationship, Drug; Embryo, Mammalian; Enzyme Inhibitors; HL-60 Cells; Humans; Kinetin; Lung; Membrane Proteins; Mice; Purines; Roscovitine; Skin; Time Factors; Up-Regulation

2007
Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase.
    Molecular cell, 1998, Volume: 2, Issue:5

    Topics: Animals; Apoptosis; Breast Neoplasms; CDC2 Protein Kinase; CDC2-CDC28 Kinases; Cell Line; Cyclin B; Cyclin B1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; DNA Fragmentation; Fibroblasts; Flow Cytometry; Humans; Kinetin; Mice; Oligonucleotides, Antisense; Paclitaxel; Protein Serine-Threonine Kinases; Purines; Receptor, ErbB-2; Transfection; Tumor Cells, Cultured; Up-Regulation

1998
Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
    Oncogene, 1999, Dec-09, Volume: 18, Issue:52

    Topics: Blotting, Western; Breast Neoplasms; Carcinoma; CDC2-CDC28 Kinases; Cell Cycle; Cell Death; Cell Line; Cell Line, Transformed; Cell Nucleolus; Cell Nucleus; Cell Transformation, Neoplastic; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme Inhibitors; G1 Phase; Humans; Inhibitory Concentration 50; Kinetin; Mitomycin; Nucleic Acid Synthesis Inhibitors; Nucleolin; Phosphoproteins; Protein Serine-Threonine Kinases; Purines; RNA-Binding Proteins; Roscovitine; Tumor Cells, Cultured; Tumor Suppressor Protein p53

1999